Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer

Phase 1/2 Completed 47 enrolled Capital Medical University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK) for unresectable locally advanced pancreatic cancer.

Timeline

Start: 2013-06-01
Primary completion: 2016-05-30
Completion: 2017-06-13

Publications

Results Jiang N, Qiao G, Wang X, Morse MA, Gwin WR, Zhou L, Song Y, Zhao Y, Chen F, Zhou X, Huang L, Hobeika A, Yi X, Xia X, Guan Y, Song J, Ren J, Lyerly HK. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clin Cancer Res. 2017 Sep 1;23(17):5066-5073. doi: 10.1158/1078-0432.CCR-17-0492. Epub 2017 Jun 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DC-CIK	Cell therapy	—	—
Subject	S-1	Small molecule	40 mg	Oral
Subject	S-1	Small molecule	50 mg	Oral
Subject	S-1	Small molecule	60 mg	Oral

Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications